Oral Delivery. Genetic Breakthroughs.

Henri Pierre is the CEO of Oragen Therapeutics and brings over 15 years of experience in the bio-pharmaceutical industry. Throughout his career, he has held senior leadership roles in major players such as joint ventures companies between Sanofi and Merck, as well as in a biotech firm (Valneva) and a startup environment. He has successfully launched six pharmaceutical products across various therapeutic areas. Henri has developed strong and versatile expertise in corporate strategy, business development & licensing, market access and marketing. His broad experience across both large organizations and agile, innovation-driven settings positions him as a strategic leader with a proven ability to create value in the biotech sector. He holds a Doctorate in Pharmacy and a Master’s in Management from Lyon University, complemented by a Diploma in Entrepreneurship from Harvard University

Ph.D. and Professor of Pharmaceutical Technology, Dr. Arnaud Beduneau is an internationally recognized expert in drug formulation, nanomedicine, and inflammatory diseases. As Chief Scientific Officer of the company, he brings over 20 years of experience bridging cutting-edge academic research and industrial innovation. He is the author or co-author of 56 scientific publications and the inventor of 5 patents. He also serves on the Scientific Advisory Board of Orinova. He is an active member of several national steering and advisory committees focused on RNA therapies and bioproduction, and has held roles in academic scientific councils, contributing to the development of research and education in pharmaceutical sciences.

Thomas Stalder is Chief Technology Officer (CTO) of the company and a hospital pharmacist. He specializes in drug formulation, nanomedicine, analytical chemistry, pharmaceutical technology, and clinical oncology pharmacy. He also works closely with the hospital’s clinical trials unit on innovative therapeutic approaches. As the inventor of the company’s core technology, he plays a key role in bridging clinical practice with technological development. His dual background in pharmacy and research supports the company’s mission to advance clinically relevant, science-driven therapeutic solutions. He holds a Doctorate in Pharmacy and a Ph.D.

Catherine has over 30 years of experience in clinical research and regulatory affairs within the biotech industry. She has developed extensive expertise in the development of innovative healthcare products, including advanced therapy medicinal products (ATMPs), from Phase 1 through Phase 3 clinical studies. Throughout her career, she has led numerous development projects, engaging with health authorities (FDA, EMA, and EU NCAs) and European payers (HTA bodies).

Catherine has held key leadership positions, including Chief Development Officer and Head of Regulatory Affairs at Coave Therapeutics, where she focused on AAV-based gene therapies for ophthalmology and neurology. She also served in similar roles at Enterome, developing peptide-based immunomodulatory drugs for oncology. Earlier in her career, she spent several years as Head of Regulatory Affairs at Transgene. She began her professional journey in clinical research at Ipsen and Sanofi Pasteur.

Catherine holds a Doctor of Pharmacy degree and a Master’s degree in toxicology.

Didier Cussac, PhD., is a pharmacologist with 20 years’ experience in drug discovery programs in pharmaceutical setting with more than 90 publications in international journals and co-authored of 9 patents. Didier have extensive management experience of multidisciplinary pharmacology research, and he has actively participated to the selection of several preclinical candidates, leading to the PoC and to the launch of several drugs on the market, especially in CNS diseases. Since 2018, Didier is an independent consultant and he provides consulting services for TTO, start-up, biotechs, and funding companies to valorize drug discovery projects. In this context, Didier will be in charge to advise and to analyse all preclinical data generated all along the lead optimisation process of Oragen's project.

Laurent Peyrin-Biroulet is a globally recognized expert in Inflammatory Bowel Disease (IBD) and Professor of Gastroenterology. He has served as President of the European Crohn’s and Colitis Organization (ECCO), President of the GETAID (Groupe d'Etude sur les Affections Inflammatoires Digestives), and Scientific Secretary of the International Organization for the Study of IBD (IOIBD). He leads numerous academic and industry clinical trials across multiple countries. He has shaped international standards through initiatives like STRIDE and development of disease severity and disability indexes. Author of 1,200+ publications (H-index 118), Laurent is ranked the top global expert in Crohn’s disease by Expertscape

Lucine Vuitton is a medical doctor and gastroenterologist, serving as Head of Clinical and Research Activities on Chronic Inflammatory Bowel Disease (IBD) at the Department of Gastroenterology and Digestive Endoscopy at Besançon University Hospital in France. With a strong commitment to both clinical care and research, she is a board member and treasurer of GETAID a leading clinical research group focused on IBD. Additionally, she serves as Vice-President of the Scientific Council of AFA France, the national patient association for Crohn’s disease and ulcerative colitis. Author or co-author of over 100 peer-reviewed publications, Lucine is recognized for her contributions to advancing the understanding and management of IBD.

Alexander Kabanov is the Mescal Swain Distinguished Professor and Director of the UNC Center for Nanotechnology in Drug Delivery at the Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Previously, he was a faculty member at the University of Nebraska Medical Center (UNMC), where he founded and led the Center for Drug Delivery and Nanomedicine, the first academic nanomedicine center in the country, from 2004 to 2012.

Kabanov has made pioneering contributions to nanomedicine, particularly in polymeric micelles, polyelectrolyte complexes, nanogels, and exosomes for therapeutic delivery in cancer and neurological diseases. A highly cited researcher in Pharmacology and Toxicology since 2014, he has authored over 360 scientific papers, holds 38 US patents, and co-founded several pharmaceutical companies.

Philippe Archinard brings over 40 years of international experience in the life sciences industry, having held senior executive roles in both multinational corporations and biotechnology companies. His career includes leadership positions such as CEO of Transgene and Deputy Director of the Mérieux Institute, where he contributed to strategic growth, innovation, and international partnerships. Philippe’s combined scientific background and business expertise position him as a valuable advisor in the development and scaling of healthcare and biotech ventures. He is a chemical engineer with a Ph.D. in biochemistry from the University of Lyon and a Program for Management Development (PMD) from Harvard Business School.

Pierre A. Morgon is an accomplished life sciences executive with over 35 years of global industry experience. He currently serves as CEO and co-founder of several human life science start-ups and holds leadership roles as Chairman or Non-Executive Director on the boards of various private and publicly listed biotech companies, as well as non-profit organizations. Throughout his career, Pierre has held senior executive (C-level) positions in multinational corporations including Sanofi and BMS. He also led innovative start-ups as CEO. In addition to his operational roles, he is actively engaged in mentoring emerging company CEOs through programs such as MassChallenge Switzerland and Israel. Pierre holds a Doctorate in Pharmacy, a Master in Business Law, and an MBA. He is also an alumnus of both INSEAD and IMD.